GH Research (GHRS) Financials: Revenue & Earnings
GHRS$21.77+1.06 +5.12%
$1.49B
Market Cap
-20.71
P/E
—
Forward P/E
67
Score
GH Research (GHRS) Financials: Revenue & Earnings
GHRS price $21.77 +1.06 +5.12%
- Ticker
- GHRS
- Price
- $21.77
- Change
- +1.06 +5.12%
- Market cap ?
- $1.49B
- P/E ?
- -20.71
- Dividend yield ?
- 0.00%
- Beta ?
- 1.32
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 67
- Value
- 49
- Quality
- 52
- Growth
- 100
Stocklytics score rationale: value 49, quality 52, growth 100.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has…
Fair value
GHRS fair value Not meaningful. Price $21.77.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | -0.31 | — | — |
| 2026-08-06 | -0.23 | -0.29 | — | — |
| 2026-05-14 | -0.31 | -0.27 | — | — |
| 2026-03-05 | -0.23 | -0.29 | — | — |
| 2025-11-06 | -0.23 | -0.23 | — | — |
| 2025-08-07 | -0.15 | -0.22 | — | — |
| 2025-05-08 | -0.19 | -0.61 | — | — |
| 2025-02-27 | -0.17 | -0.23 | — | — |
| 2024-11-14 | -0.23 | -0.25 | — | — |
| 2024-09-03 | -0.20 | -0.23 | — | — |
| 2024-05-03 | -0.15 | -0.22 | — | — |
| 2024-02-29 | -0.21 | -0.20 | — | — |
| 2023-11-09 | -0.11 | -0.20 | — | — |
| 2023-08-23 | -0.15 | -0.25 | — | — |
| 2023-05-11 | -0.21 | -0.22 | — | — |
| 2023-03-02 | -0.32 | -0.17 | — | — |
| 2022-11-10 | -0.01 | -0.17 | — | — |
| 2022-08-23 | 0.01 | -0.17 | — | — |
| 2022-05-18 | -0.11 | -0.16 | — | — |
| 2022-03-28 | -0.09 | -0.17 | — | — |
| 2021-12-06 | -0.04 | -0.10 | — | — |
| 2021-09-23 | -0.05 | -0.08 | — | — |
| 2021-06-28 | -0.02 | — | — | — |
| 2020-12-31 | -0.01 | — | — | — |
| 2020-09-30 | -0.00 | — | — | — |
| 2020-06-30 | -0.00 | — | — | — |
| 2020-03-31 | -0.00 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Schonharting Florian | Buy | 2.30K | $0.03 | 58 |
| 2026-08-11 | Moore Duncan | Buy | 2.20K | $0.03 | 55 |
| 2026-08-11 | Hanley Dermot John | Buy | 2.20K | $0.03 | 55 |
| 2026-08-11 | Forer Michael | Buy | 100.00K | $0.03 | 2.50K |
| 2026-08-11 | Forer Michael | Buy | 2.20K | $0.03 | 55 |
| 2026-04-01 | Schonharting Florian | Other | 0 | — | — |
| 2026-03-18 | Moore Duncan | Other | 0 | — | — |
| 2026-03-18 | Moore Duncan | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Cameron Aaron Luke | Other | 33.21K | $21.32 | 708.06K |
| 2026-03-18 | Cameron Aaron Luke | Other | 100.00K | $0.03 | 2.50K |
| 2026-03-18 | Cameron Aaron Luke | Other | 25.00K | $5.80 | 145.00K |
| 2026-03-18 | Hanley Dermot John | Other | 0 | — | — |
| 2026-03-18 | Hanley Dermot John | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Halle Magnus Clemensen | Other | 0 | — | — |
| 2026-03-18 | Halle Magnus Clemensen | Other | 50.00K | $0.03 | 1.25K |
| 2026-03-18 | Forer Michael | Other | 0 | — | — |
| 2026-03-18 | Forer Michael | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Valcheva Velichka | Other | 50.00K | $10.83 | 541.50K |
| 2026-03-18 | Valcheva Velichka | Other | 35.00K | $7.59 | 265.65K |
| 2026-03-18 | Valcheva Velichka | Other | 300.00K | $0.03 | 7.50K |
| 2026-03-18 | Ryan Julie | Other | 50.49K | $12.32 | 622.00K |
| 2026-03-18 | Ryan Julie | Other | 30.00K | $0.03 | 750 |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 68, holders +13 vs prior quarter. Ownership 77.41%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 13.26M | 2.50M | +23.23% | 356.52M |
| BVF INC/IL | 8.65M | 0 | 0.00% | 232.52M |
| RA CAPITAL MANAGEMENT, L.P. | 7.64M | -39.88K | -0.52% | 205.28M |
| FMR LLC | 5.98M | 841.00K | +16.37% | 160.66M |
| RTW INVESTMENTS, LP | 5.93M | 0 | 0.00% | 159.50M |
| DEEP TRACK CAPITAL, LP | 3.33M | 3.33M | New | 89.60M |
| AVORO CAPITAL ADVISORS LLC | 1.80M | 0 | 0.00% | 48.38M |
| FORESITE CAPITAL MANAGEMENT VI LLC | 940.49K | 625.00K | +198.10% | 25.28M |
| JEFFERIES FINANCIAL GROUP INC. | 712.30K | 0 | 0.00% | 19.15M |
| BLACKROCK, INC. | 480.29K | 24.67K | +5.41% | 12.91M |
| UBS GROUP AG | 477.41K | 64.99K | +15.76% | 12.83M |
| MILLENNIUM MANAGEMENT LLC | 323.40K | -614.50K | -65.52% | 8.69M |
| BRAIDWELL LP | 207.24K | 207.24K | New | 5.57M |
| BOOTHBAY FUND MANAGEMENT, LLC | 202.10K | -80.79K | -28.56% | 5.43M |
| JANE STREET GROUP, LLC | 169.95K | 169.95K | New | 4.57M |
| HIGHVISTA STRATEGIES LLC | 158.77K | -54.44K | -25.53% | 4.27M |
| TREXQUANT INVESTMENT LP | 153.77K | 83.96K | +120.27% | 4.13M |
| GOLDMAN SACHS GROUP INC | 148.67K | 103.88K | +231.90% | 4.00M |
| XTX TOPCO LTD | 86.99K | 34.90K | +66.99% | 2.34M |
| CITADEL ADVISORS LLC | 85.95K | 85.95K | New | 2.31M |
| ADVISORSHARES INVESTMENTS LLC | 71.27K | 4.23K | +6.31% | 1.92M |
| CENTERBOOK PARTNERS LP | 69.44K | -147.14K | -67.94% | 1.87M |
| HRT FINANCIAL LP | 65.38K | 65.38K | New | 1.76M |
| MORGAN STANLEY | 52.22K | 26.39K | +102.16% | 1.40M |
| POINT72 ASSET MANAGEMENT, L.P. | 50.88K | 50.88K | New | 1.37M |
Earnings and financials
GH Research PLC (GHRS) trades at $21.77, with a market cap of $1.49B and a trailing P/E of -20.71. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn